Decoding the Hype and Fear of Nanomedicines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Decoding the Hype and Fear of Nanomedicines
Does nanotechnology offer a cure-all or a kill all? We speak with Ruth Duncan about the real potential of nanomedicines.


Pharmaceutical Technology Europe
Volume 24, Issue 2

Q: What key factors are necessary to develop practical, safe and effective nanomedicines?

As with any medicine, an understanding of the critical product attributes that govern safety and efficacy is vitally important, as well as the ability to ensure characterisation of these parameters using validated analytical techniques. With nanomedicines, it is also important to consider the route of administration, dose, frequency of administration, fate of the nanomaterial (all components from the product), any detrimental bioactivity, antigenicity, immunogenicity and haematocompatibility.

As nano-sized medicines often display very different pharmacokinetics and body distribution compared with low-molecular chemical entities at the whole body and cellular level, the pharmacokinetics–pharmacodynamics relationship needs to be carefully considered during the establishment of critical product attributes relating to safety and efficacy. For each product, it is also essential to consider the proposed clinical setting for use.

Ruth Duncan is Professor Emerita at Cardiff University (UK), and visiting professor at CIPF (Spain) and the University of Greenwich (UK).

References

1. R. Duncan and R. Gaspar, "Nanomedicine(s) under the microscope", Mol. Pharmaceutics online, DOI: 10.1021/mp200394t, 5 Oct., 2011.

2. B. Munos, Nat. Rev. Drug Discov., 8(12), 959–968 (2009).

3. R.A. Petros and J.M. DeSimone, Rev. Drug Discov., 9(8), 615–627 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here